CARA - Cara Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
23.92
+1.72 (+7.75%)
At close: 4:00PM EDT

24.25 +0.33 (1.38%)
After hours: 7:39PM EDT

Stock chart is not supported by your current browser
Previous Close22.20
Open22.38
Bid24.10 x 3000
Ask24.37 x 800
Day's Range22.30 - 24.01
52 Week Range11.11 - 24.01
Volume1,598,894
Avg. Volume972,243
Market Cap939.829M
Beta3.53
PE Ratio (TTM)N/A
EPS (TTM)-1.85
Earnings DateAug 3, 2017 - Aug 7, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.88
Trade prices are not sourced from all markets
  • ACCESSWIRE2 days ago

    CBD Stocks Set to Explode

    HENDERSON, NV / ACCESSWIRE / September 19, 2018 / It's just a matter of time before medical marijuana will become legal in all 50 states. It's not surprising when you consider a recent poll shows 93% of ...

  • ACCESSWIRE2 days ago

    Today's Research Reports on Trending Tickers: Madrigal Pharmaceuticals and Cara Therapeutics

    NEW YORK, NY / ACCESSWIRE / September 19, 2018 / U.S. markets closed up Tuesday on the strength of upbeat corporate earnings and strong economic data. On Tuesday, China announced tariffs of between 5 to ...

  • ACCESSWIRE6 days ago

    Major Stem Cell Breakthroughs Giving Investors Big Opportunity

    HENDERSON, NV / ACCESSWIRE / September 14, 2018 / Last week, Sangamo Therapeutics became the first company to edit a patient's DNA inside the body, usually the process is done outside the body. This is ...

  • Benzinga7 days ago

    Jefferies Projects $573M Peak Sales For Cara Therapeutics' Lead Candidate

    Cara Therapeutics Inc (NASDAQ: CARA ), a biotech company developing non-opioid pain relief drugs, has earned a bullish review from Jefferies.  The Analyst Analyst Matthew Andrews initiated coverage of Cara ...

  • Better Buy: Cara Therapeutics Inc. vs. Fresenius Medical Care AG & Co.
    Motley Fool8 days ago

    Better Buy: Cara Therapeutics Inc. vs. Fresenius Medical Care AG & Co.

    Which stock wins in a one-on-one matchup between these two partners?

  • 9 Marijuana Stocks to Play the Pot Craze
    InvestorPlace9 days ago

    9 Marijuana Stocks to Play the Pot Craze

    Marijuana stocks, fueled by what may well be the biggest legal and medical revolution in years, have already proven they’re blazing their own trail. In all cases, though, there’s explosive potential on the table — the legal marijuana industry’s story has just gotten that compelling, as more states seek to legalize it while regulators finally start to see its legitimate medical benefits. Of all the marijuana stocks worth a look right now, Canopy Growth (NYSE:CGC) has garnered the most attention of late.

  • GlobeNewswire15 days ago

    Cara Therapeutics to Present at the 27th European Academy of Dermatology & Venereology Congress

    STAMFORD, Conn., Sept. 05, 2018-- Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively ...

  • Here's Why Cara Therapeutics Rose 12.5% in August
    Motley Fool16 days ago

    Here's Why Cara Therapeutics Rose 12.5% in August

    The company announced second-quarter 2018 earnings results and initiated a crucial late-stage clinical trial.

  • How Cara Therapeutics’ Top Line Is Trending
    Market Realist20 days ago

    How Cara Therapeutics’ Top Line Is Trending

    Cara’s product candidate Korsuva has demonstrated improvement in pruritus patients’ quality of life as well as efficacy in patients with moderate-to-severe pain without the side effects that are generally associated with opioid pain therapeutics currently on the market. The general and administrative expenses that Cara Therapeutics (CARA) has incurred increased from $2.67 million in the second quarter of 2017 to $3.68 million in the second quarter. Part 1 - How Is Insys Therapeutics Positioned in H2 2018?

  • Why Analysts Remain Bullish on Cara Therapeutics
    Market Realist20 days ago

    Why Analysts Remain Bullish on Cara Therapeutics

    Cara Therapeutics’ (CARA) other income increased from $331,000 in the second quarter of 2017 to $467,000 in the second quarter of 2018. The company received an income tax benefit of $152,000 in the second quarter of this year as compared to an income tax benefit of $2,000 in the second quarter of 2017.

  • How Is Insys Therapeutics Positioned in H2 2018?
    Market Realist20 days ago

    How Is Insys Therapeutics Positioned in H2 2018?

    The US government is taking steps to address the opioid epidemic and rapidly rising addiction levels in the country. On August 16, President Trump asked the Attorney General to start filing federal lawsuits against certain companies that supply opioids to hospitals. In this series, we’ll analyze the financial performance, products, analysts’ views, valuation metrics, and the stock performance of Insys Therapeutics (INSY), Cara Therapeutics (CARA), Collegium Pharmaceutical (COLL), and Pacira Pharmaceuticals (PCRX).

  • GlobeNewswire25 days ago

    Analysis: Positioning to Benefit within C&J Energy Services, LivePerson, Kadmon, Cara Therapeutics, CorMedix, and Second Sight Medical Products — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Aug. 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of C&J ...

  • Thomson Reuters StreetEventslast month

    Edited Transcript of CARA earnings conference call or presentation 7-Aug-18 8:30pm GMT

    Q2 2018 Cara Therapeutics Inc Earnings Call

  • 3 Reasons Cara Therapeutics Is a Great Pick for Aggressive Investors
    Motley Foollast month

    3 Reasons Cara Therapeutics Is a Great Pick for Aggressive Investors

    This biotech could deliver big returns for investors who aren't afraid of taking on considerable risk.

  • Benzingalast month

    4 Cannabis Stocks In Uptrends This Week

    It’s been an eventful few weeks in the cannabis market. Between Tilray Inc (NASDAQ: TLRY) IPOing to become the first cannabis-producing company on a major American exchange, Aurora Cannabis’ (OTC: ACBFF) $2.5 billion acquisition of Medreleaf Corp (OTC: MEDFF), and Acreage Holdings’ $119 million capital raise, headlines definitely have not been in short supply of late. Here are four cannabis stocks that short-term traders should have their eye on this week.To identify the trend we used VantagePoint Software, a market forecasting software that uses artificial intelligence to predict price action 1-3 days in advance with up to 86 percent accuracy.

  • ACCESSWIRElast month

    Biotech and Cannabis Companies Set to Own The Future

    HENDERSON, NV / ACCESSWIRE / August 8, 2018 / With investors piling into biotechnology, and cannabis stocks the future is upon us. Intelligent investors see the writing on the wall. Biotechnology, and ...

  • Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates
    Zackslast month

    Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates

    Cara (CARA) delivered earnings and revenue surprises of -4.00% and 359.84%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Cara: 2Q Earnings Snapshot

    On a per-share basis, the Stamford, Connecticut-based company said it had a loss of 52 cents. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...

  • GlobeNewswirelast month

    Cara Therapeutics Reports Second Quarter 2018 Financial Results

    STAMFORD, Conn., Aug. 07, 2018-- Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively ...

  • GlobeNewswirelast month

    Cara Therapeutics Doses First Patient in Second Pivotal Phase 3 Efficacy Trial of KORSUVA™ (CR845/difelikefalin) Injection in Hemodialysis Patients with Chronic Kidney Disease-Associated Pruritus

    Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced the dosing of the first patient in its second pivotal Phase 3 efficacy trial (KALM™-2) of KORSUVA™ (CR845/difelikefalin) injection in hemodialysis patients suffering from moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). The global trial is expected to enroll hemodialysis patients in the U.S., Europe and some countries in the Pacific Rim region. The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to KORSUVA™ injection for this indication, for which there are currently no approved therapies in the U.S. or European Union (EU).

  • GlobeNewswire2 months ago

    Cara Therapeutics Appoints Christopher A. Posner to Board of Directors

    Cara Therapeutics, Inc. (CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced the appointment of Christopher A. Posner to its Board of Directors. “We are pleased to welcome Chris to our board,” said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics.

  • GlobeNewswire2 months ago

    Cara Therapeutics to Announce Second Quarter 2018 Financial Results on August 7, 2018

    STAMFORD, Conn., July 31, 2018-- Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain ...

  • ACCESSWIRE2 months ago

    Initiating Free Research Reports on Celgene and Three Other Biotech Equities

    Stock Research Monitor: CARA, CLDX, and CORT LONDON, UK / ACCESSWIRE / July 27, 2018 / If you want a free Stock Review on CELG sign up now at www.wallstequities.com/registration . On Thursday, benchmark ...

  • ACCESSWIRE2 months ago

    This Unknown Stock Could Trade From $3 to $10 As Wall Street Wakes Up

    CNS disorders are seeing renewed interest from investors, and epilepsy has seen a particular resurgence in investor activity as numerous public companies have found success with new drugs and mechanisms. A little-known company called NeuroOne Medical (NMTC) is making strides with an all-new thin-film electrode technology, which comes from the labs of the Mayo Clinic. This prestigious institute is also a 10% stockholder in newly public NMTC.

  • GlobeNewswire2 months ago

    Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    STAMFORD, Conn., July 23, 2018-- Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain ...